<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Jubilant Ingrevia Ltd - Mar 2025 Earnings Call Transcript Analysis | Financial Report Insights
    
</title>
<link href="/_pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/_pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/jubilant-ingrevia-ltd---mar-2025-earnings-call-transcript-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/jubilant-ingrevia-ltd---mar-2025-earnings-call-transcript-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Jubilant Ingrevia Ltd - Mar 2025 Earnings Call Transcript Analysis">
  <meta property="og:description" content="Earnings Call Transcript Analysis Report # Financial Performance # Key Financial Metrics # Revenue, EBITDA, ROCE, Net Debt to EBITDA ratio, Asset Turnover, Cash Conversion. Current Results vs. Previous Quarters/YoY # Trailing 12 months (2024): Revenue Rs. 4,200cr, aiming for Rs. 12,000cr by 2030. EBITDA: Aiming for Rs. 2,000cr by 2030 (4x growth). Current EBITDA margin improved from 9.5% to 14% over the last 4-5 quarters. ROCE: Improved from 9-10% to 12% in the last 4 quarters, targeting 17-20%. Specialty portfolio grew 20% in the first 9 months of the year. Nutrition business grew 8% (volume growth ~15%). Chemical Intermediates (acetyls) business faced challenges due to market conditions. US and Europe have shown the fastest growth in revenue. The US market grew from 4-5% to 9% of the revenue mix last quarter. Cost reduction of Rs. 120cr achieved this year. Net Debt: Target is to reduce from 1.5 to 1.2-1.3. Cash Conversion: Improved from sub 90% to 100%. Revised Guidance/Forecasts # “Pinnacle 345” strategy: 3x revenue growth, 4x EBITDA growth in 5 years (by 2030). Organically, the company has a “bottom-up” plan that takes them to almost Rs. 10,000 crores with a 2,000 crore gap that they are working to fill inorganically. Targeting Rs. 12,000cr revenue and Rs. 2,000cr EBITDA by FY30. ROCE target of 17-20%. Net Debt to EBITDA target of 1.2-1.3. Areas of Growth/Decline # Growth: Specialty Chemicals (particularly CDMO and Fine Chemicals), Nutrition. Decline: Chemical Intermediates (acetyls) faced headwinds, but management expects recovery. Strategic Initiatives &amp; Business Updates # Major Strategic Announcements # “Pinnacle 345” strategy: Focus on customer centricity, world-class operations, innovation, ESG, and people. Shift towards Specialty Chemicals and Nutrition, reducing reliance on Chemical Intermediates. Focus on exports, particularly to the US and Europe. Aiming for 70% from exports. Increased customer-focused product development. New Products, Services, or Markets # Diketene derivatives platform (growing rapidly). Expansion in cosmetics (skincare and haircare). Semiconductor chemicals (early stages, 8-10 molecules in the pipeline). Oil field chemicals (growing segment). Human Nutrition (Vitamin B3 food grade, choline chloride). Pre-mixes and formulations in Human Nutrition. New foray into the Japanese Market. Operational Changes # Significant organizational restructuring, with ~50% of leadership roles changing in the last 1.5-2 years. Increased investment in R&amp;D (targeting to double R&amp;D spend). Implementation of digital interventions (200&#43; interventions, World Economic Forum - Lighthouse Network Award). Enhanced focus on ESG (top 5% of global chemical companies with ECOVARDIS gold rating). Revamped safety programs. Key Account Management (KAM) initiative for top 30-35 customers. Ongoing/Completed Projects # Two major CDMO contracts in Agro (construction ongoing, revenue expected from Q4 FY26 and mid-calendar year 2025). Commissioned new plant for Vitamin B3 (cosmetics and food grade). Expansion of Diketene derivatives portfolio. USFDA Clearance. Market &amp; Competitive Landscape # Industry Trends # Favorable macroeconomic conditions for India (China&#43;1, trade wars). Secular growth in Pharma, Agrochemicals, Nutrition, and Consumer sectors. Outsourcing to India expected to grow at 15%&#43;. Semiconductor chemicals market gradually opening up to outsourcing. Competitive Positioning Statements # Globally number 1 in bio-pyridine and beta-picoline. Number 1 in 35 out of ~50 Pyridine derivatives. Globally number 2 in Vitamin B3 (aiming for number 1). Domestic leader in choline chloride (Vitamin B4). Globally number 1 or 2 in merchant market capacity for acetic anhydride. Captured 70% of the market share of a US competitor in Pyridine that closed down. Market Challenges/Opportunities # Challenges: Oversupply in China, impacting prices in some segments. Opportunities: Growing demand in Specialty Chemicals, Nutrition, and CDMO. “Opportunities in the US market, and looking to expand in Japan.” Market Share/Positioning # Pyridine and Picolines: 25%&#43; global market share. Acetic Anhydride: 75%&#43; market share in the domestic market. Risk Factors &amp; Challenges # Concerns/Challenges Acknowledged # Market volatility and overcapacity in China impacting prices. Challenges in paracetamol and acetate markets impacting acetic anhydride demand. Dependence on external factors. Market Uncertainties # Uncertainty around global trade tariffs. Volatility in commodity cycles (particularly for acetyls). Forward-Looking Statements # Outlook and Future Projections # “Pinnacle 345” strategy: 3x revenue, 4x EBITDA by FY30. Specialty and Nutrition to become 75-80% of the portfolio. Exports to become 60-65% of the portfolio. US to become 20-25% of the portfolio. Continued growth in CDMO, Fine Chemicals, and Nutrition. Commitments/Targets # ROCE target of 17-20%. Net Debt to EBITDA target of 1.2-1.3. Doubling R&amp;D spend. Becoming top 3 globally in Diketene derivatives. 5x growth in CDMO business in the next two years, and 7X by FY30. Planned Investments/Strategic Priorities # Continued investment in R&amp;D and technology. Capex for CDMO, multi-purpose plants, and GMP facility. Expansion in Human Nutrition (pre-mixes, formulations). Focus on inorganic growth opportunities. Focus on growing into US, European and Japanese markets. Q&amp;A Insights # Most Pressing Analyst Questions # Details on customer interactions and conversion rates. Breakdown of Pyridine derivatives and their contribution. Retention of the new leadership team. Market size and applications for oil field chemicals. Asset turnover expectations for Specialty Chemicals. Capex funding strategy. Incremental savings plan and drivers. Inorganic growth strategy. Impact of US tariffs. CDMO pipeline mix (pyridine vs. non-pyridine). Pharma CDMO differentiation from Jubilant Pharmova. New Information Revealed # 70% of Pharma CDMO business is currently non-pyridine. One of the two major Agro CDMO contracts is non-pyridine. Actively looking at inorganic growth opportunities. Detailed breakdown of cost-saving initiatives. The future revenue growth mix of Pyridine and Non-Pyridine based chemicals. Management Tone &amp; Sentiment # Overall Tone # Confident, optimistic, and focused. Changes in Language # More emphasis on customer centricity, innovation, and ESG. Areas of Confidence/Concern # Confidence: CDMO, Fine Chemicals, Nutrition, strategic shift, operational improvements, ESG initiatives. Concern: Market volatility and competition in Chemical Intermediates (acetyls), but with a plan to address it. Summary of Most Important Takeaways # Jubilant Ingrevia is undergoing a significant transformation, shifting its focus from Chemical Intermediates to higher-margin Specialty Chemicals and Nutrition businesses. The “Pinnacle 345” strategy outlines ambitious growth targets (3x revenue, 4x EBITDA by FY30), driven by CDMO, Fine Chemicals, and expansion in new areas like cosmetics and semiconductors. The company has made substantial progress in the last 1.5 years, with organizational restructuring, increased R&amp;D investment, and digital interventions. While market challenges exist (particularly in acetyls), management is confident in their ability to execute their strategy and deliver on their targets. The emphasis on customer centricity, innovation, and ESG positions the company for sustainable long-term growth. The company is also clearly focused on increasing exports, exploring inorganic growth opportunities, and are well-funded to meet their objectives. Download Transcript">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2025-03-06T22:34:31+00:00">
    <meta property="article:modified_time" content="2025-03-06T22:34:31+00:00">
    <meta property="article:tag" content="Jubilant Ingrevia Ltd.">
    <meta property="article:tag" content="JUBLINGREA">
    <meta property="article:tag" content="Speciality Chemicals - Diversified">
    <meta property="article:tag" content="Materials">
    <meta property="article:tag" content="Small Cap">
    <meta property="article:tag" content="Earnings Call">













<link rel="stylesheet" href="/assets/combined.min.83aead7461ea8e7fcfbb79b8c9400e1ec33efe08796484ba7a94d30f7b4923a8.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/jubilant-ingrevia-ltd---mar-2025-earnings-call-transcript-analysis/">Jubilant Ingrevia Ltd - Mar 2025 Earnings Call Transcript Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Jubilant Ingrevia Ltd - Mar 2025 Earnings Call Transcript Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2025-03-06T22:34:31&#43;00:00">March 6, 2025</time>
      

      
      &nbsp; · &nbsp;
      6 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/jubilant-ingrevia-ltd./">#Jubilant Ingrevia Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/jublingrea/">#JUBLINGREA</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/speciality-chemicals---diversified/">#Speciality Chemicals - Diversified</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/materials/">#Materials</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/small-cap/">#Small Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/earnings-call/">#Earnings Call</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#earnings-call-transcript-analysis-report">Earnings Call Transcript Analysis Report</a></li>
    <li><a href="#financial-performance">Financial Performance</a>
      <ul>
        <li><a href="#key-financial-metrics">Key Financial Metrics</a></li>
        <li><a href="#current-results-vs-previous-quartersyoy">Current Results vs. Previous Quarters/YoY</a></li>
        <li><a href="#revised-guidanceforecasts">Revised Guidance/Forecasts</a></li>
        <li><a href="#areas-of-growthdecline">Areas of Growth/Decline</a></li>
      </ul>
    </li>
    <li><a href="#strategic-initiatives--business-updates">Strategic Initiatives &amp; Business Updates</a>
      <ul>
        <li><a href="#major-strategic-announcements">Major Strategic Announcements</a></li>
        <li><a href="#new-products-services-or-markets">New Products, Services, or Markets</a></li>
        <li><a href="#operational-changes">Operational Changes</a></li>
        <li><a href="#ongoingcompleted-projects">Ongoing/Completed Projects</a></li>
      </ul>
    </li>
    <li><a href="#market--competitive-landscape">Market &amp; Competitive Landscape</a>
      <ul>
        <li><a href="#industry-trends">Industry Trends</a></li>
        <li><a href="#competitive-positioning-statements">Competitive Positioning Statements</a></li>
        <li><a href="#market-challengesopportunities">Market Challenges/Opportunities</a></li>
        <li><a href="#market-sharepositioning">Market Share/Positioning</a></li>
      </ul>
    </li>
    <li><a href="#risk-factors--challenges">Risk Factors &amp; Challenges</a>
      <ul>
        <li><a href="#concernschallenges-acknowledged">Concerns/Challenges Acknowledged</a></li>
        <li><a href="#market-uncertainties">Market Uncertainties</a></li>
      </ul>
    </li>
    <li><a href="#forward-looking-statements">Forward-Looking Statements</a>
      <ul>
        <li><a href="#outlook-and-future-projections">Outlook and Future Projections</a></li>
        <li><a href="#commitmentstargets">Commitments/Targets</a></li>
        <li><a href="#planned-investmentsstrategic-priorities">Planned Investments/Strategic Priorities</a></li>
      </ul>
    </li>
    <li><a href="#qa-insights">Q&amp;A Insights</a>
      <ul>
        <li><a href="#most-pressing-analyst-questions">Most Pressing Analyst Questions</a></li>
        <li><a href="#new-information-revealed">New Information Revealed</a></li>
      </ul>
    </li>
    <li><a href="#management-tone--sentiment">Management Tone &amp; Sentiment</a>
      <ul>
        <li><a href="#overall-tone">Overall Tone</a></li>
        <li><a href="#changes-in-language">Changes in Language</a></li>
        <li><a href="#areas-of-confidenceconcern">Areas of Confidence/Concern</a></li>
      </ul>
    </li>
    <li><a href="#summary-of-most-important-takeaways">Summary of Most Important Takeaways</a></li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="earnings-call-transcript-analysis-report">
  Earnings Call Transcript Analysis Report
  <a class="anchor" href="#earnings-call-transcript-analysis-report">#</a>
</h2>
<h2 class="heading" id="financial-performance">
  Financial Performance
  <a class="anchor" href="#financial-performance">#</a>
</h2>
<h3 class="heading" id="key-financial-metrics">
  Key Financial Metrics
  <a class="anchor" href="#key-financial-metrics">#</a>
</h3>
<ul>
<li>Revenue, EBITDA, ROCE, Net Debt to EBITDA ratio, Asset Turnover, Cash Conversion.</li>
</ul>
<h3 class="heading" id="current-results-vs-previous-quartersyoy">
  Current Results vs. Previous Quarters/YoY
  <a class="anchor" href="#current-results-vs-previous-quartersyoy">#</a>
</h3>
<ul>
<li>Trailing 12 months (2024): Revenue Rs. 4,200cr, aiming for Rs. 12,000cr by 2030.</li>
<li>EBITDA: Aiming for Rs. 2,000cr by 2030 (4x growth). Current EBITDA margin improved from 9.5% to 14% over the last 4-5 quarters.</li>
<li>ROCE: Improved from 9-10% to 12% in the last 4 quarters, targeting 17-20%.</li>
<li>Specialty portfolio grew 20% in the first 9 months of the year.</li>
<li>Nutrition business grew 8% (volume growth ~15%).</li>
<li>Chemical Intermediates (acetyls) business faced challenges due to market conditions.</li>
<li>US and Europe have shown the fastest growth in revenue. The US market grew from 4-5% to 9% of the revenue mix last quarter.</li>
<li>Cost reduction of Rs. 120cr achieved this year.</li>
<li>Net Debt: Target is to reduce from 1.5 to 1.2-1.3.</li>
<li>Cash Conversion: Improved from sub 90% to 100%.</li>
</ul>
<h3 class="heading" id="revised-guidanceforecasts">
  Revised Guidance/Forecasts
  <a class="anchor" href="#revised-guidanceforecasts">#</a>
</h3>
<ul>
<li>&ldquo;Pinnacle 345&rdquo; strategy: 3x revenue growth, 4x EBITDA growth in 5 years (by 2030).</li>
<li>Organically, the company has a &ldquo;bottom-up&rdquo; plan that takes them to almost Rs. 10,000 crores with a 2,000 crore gap that they are working to fill inorganically.</li>
<li>Targeting Rs. 12,000cr revenue and Rs. 2,000cr EBITDA by FY30.</li>
<li>ROCE target of 17-20%.</li>
<li>Net Debt to EBITDA target of 1.2-1.3.</li>
</ul>
<h3 class="heading" id="areas-of-growthdecline">
  Areas of Growth/Decline
  <a class="anchor" href="#areas-of-growthdecline">#</a>
</h3>
<ul>
<li>Growth: Specialty Chemicals (particularly CDMO and Fine Chemicals), Nutrition.</li>
<li>Decline: Chemical Intermediates (acetyls) faced headwinds, but management expects recovery.</li>
</ul>
<h2 class="heading" id="strategic-initiatives--business-updates">
  Strategic Initiatives &amp; Business Updates
  <a class="anchor" href="#strategic-initiatives--business-updates">#</a>
</h2>
<h3 class="heading" id="major-strategic-announcements">
  Major Strategic Announcements
  <a class="anchor" href="#major-strategic-announcements">#</a>
</h3>
<ul>
<li>&ldquo;Pinnacle 345&rdquo; strategy: Focus on customer centricity, world-class operations, innovation, ESG, and people.</li>
<li>Shift towards Specialty Chemicals and Nutrition, reducing reliance on Chemical Intermediates.</li>
<li>Focus on exports, particularly to the US and Europe. Aiming for 70% from exports.</li>
<li>Increased customer-focused product development.</li>
</ul>
<h3 class="heading" id="new-products-services-or-markets">
  New Products, Services, or Markets
  <a class="anchor" href="#new-products-services-or-markets">#</a>
</h3>
<ul>
<li>Diketene derivatives platform (growing rapidly).</li>
<li>Expansion in cosmetics (skincare and haircare).</li>
<li>Semiconductor chemicals (early stages, 8-10 molecules in the pipeline).</li>
<li>Oil field chemicals (growing segment).</li>
<li>Human Nutrition (Vitamin B3 food grade, choline chloride).</li>
<li>Pre-mixes and formulations in Human Nutrition.</li>
<li>New foray into the Japanese Market.</li>
</ul>
<h3 class="heading" id="operational-changes">
  Operational Changes
  <a class="anchor" href="#operational-changes">#</a>
</h3>
<ul>
<li>Significant organizational restructuring, with ~50% of leadership roles changing in the last 1.5-2 years.</li>
<li>Increased investment in R&amp;D (targeting to double R&amp;D spend).</li>
<li>Implementation of digital interventions (200+ interventions, World Economic Forum - Lighthouse Network Award).</li>
<li>Enhanced focus on ESG (top 5% of global chemical companies with ECOVARDIS gold rating).</li>
<li>Revamped safety programs.</li>
<li>Key Account Management (KAM) initiative for top 30-35 customers.</li>
</ul>
<h3 class="heading" id="ongoingcompleted-projects">
  Ongoing/Completed Projects
  <a class="anchor" href="#ongoingcompleted-projects">#</a>
</h3>
<ul>
<li>Two major CDMO contracts in Agro (construction ongoing, revenue expected from Q4 FY26 and mid-calendar year 2025).</li>
<li>Commissioned new plant for Vitamin B3 (cosmetics and food grade).</li>
<li>Expansion of Diketene derivatives portfolio.</li>
<li>USFDA Clearance.</li>
</ul>
<h2 class="heading" id="market--competitive-landscape">
  Market &amp; Competitive Landscape
  <a class="anchor" href="#market--competitive-landscape">#</a>
</h2>
<h3 class="heading" id="industry-trends">
  Industry Trends
  <a class="anchor" href="#industry-trends">#</a>
</h3>
<ul>
<li>Favorable macroeconomic conditions for India (China+1, trade wars).</li>
<li>Secular growth in Pharma, Agrochemicals, Nutrition, and Consumer sectors.</li>
<li>Outsourcing to India expected to grow at 15%+.</li>
<li>Semiconductor chemicals market gradually opening up to outsourcing.</li>
</ul>
<h3 class="heading" id="competitive-positioning-statements">
  Competitive Positioning Statements
  <a class="anchor" href="#competitive-positioning-statements">#</a>
</h3>
<ul>
<li>Globally number 1 in bio-pyridine and beta-picoline.</li>
<li>Number 1 in 35 out of ~50 Pyridine derivatives.</li>
<li>Globally number 2 in Vitamin B3 (aiming for number 1).</li>
<li>Domestic leader in choline chloride (Vitamin B4).</li>
<li>Globally number 1 or 2 in merchant market capacity for acetic anhydride.</li>
<li>Captured 70% of the market share of a US competitor in Pyridine that closed down.</li>
</ul>
<h3 class="heading" id="market-challengesopportunities">
  Market Challenges/Opportunities
  <a class="anchor" href="#market-challengesopportunities">#</a>
</h3>
<ul>
<li>Challenges: Oversupply in China, impacting prices in some segments.</li>
<li>Opportunities: Growing demand in Specialty Chemicals, Nutrition, and CDMO.</li>
<li>&ldquo;Opportunities in the US market, and looking to expand in Japan.&rdquo;</li>
</ul>
<h3 class="heading" id="market-sharepositioning">
  Market Share/Positioning
  <a class="anchor" href="#market-sharepositioning">#</a>
</h3>
<ul>
<li>Pyridine and Picolines: 25%+ global market share.</li>
<li>Acetic Anhydride: 75%+ market share in the domestic market.</li>
</ul>
<h2 class="heading" id="risk-factors--challenges">
  Risk Factors &amp; Challenges
  <a class="anchor" href="#risk-factors--challenges">#</a>
</h2>
<h3 class="heading" id="concernschallenges-acknowledged">
  Concerns/Challenges Acknowledged
  <a class="anchor" href="#concernschallenges-acknowledged">#</a>
</h3>
<ul>
<li>Market volatility and overcapacity in China impacting prices.</li>
<li>Challenges in paracetamol and acetate markets impacting acetic anhydride demand.</li>
<li>Dependence on external factors.</li>
</ul>
<h3 class="heading" id="market-uncertainties">
  Market Uncertainties
  <a class="anchor" href="#market-uncertainties">#</a>
</h3>
<ul>
<li>Uncertainty around global trade tariffs.</li>
<li>Volatility in commodity cycles (particularly for acetyls).</li>
</ul>
<h2 class="heading" id="forward-looking-statements">
  Forward-Looking Statements
  <a class="anchor" href="#forward-looking-statements">#</a>
</h2>
<h3 class="heading" id="outlook-and-future-projections">
  Outlook and Future Projections
  <a class="anchor" href="#outlook-and-future-projections">#</a>
</h3>
<ul>
<li>&ldquo;Pinnacle 345&rdquo; strategy: 3x revenue, 4x EBITDA by FY30.</li>
<li>Specialty and Nutrition to become 75-80% of the portfolio.</li>
<li>Exports to become 60-65% of the portfolio.</li>
<li>US to become 20-25% of the portfolio.</li>
<li>Continued growth in CDMO, Fine Chemicals, and Nutrition.</li>
</ul>
<h3 class="heading" id="commitmentstargets">
  Commitments/Targets
  <a class="anchor" href="#commitmentstargets">#</a>
</h3>
<ul>
<li>ROCE target of 17-20%.</li>
<li>Net Debt to EBITDA target of 1.2-1.3.</li>
<li>Doubling R&amp;D spend.</li>
<li>Becoming top 3 globally in Diketene derivatives.</li>
<li>5x growth in CDMO business in the next two years, and 7X by FY30.</li>
</ul>
<h3 class="heading" id="planned-investmentsstrategic-priorities">
  Planned Investments/Strategic Priorities
  <a class="anchor" href="#planned-investmentsstrategic-priorities">#</a>
</h3>
<ul>
<li>Continued investment in R&amp;D and technology.</li>
<li>Capex for CDMO, multi-purpose plants, and GMP facility.</li>
<li>Expansion in Human Nutrition (pre-mixes, formulations).</li>
<li>Focus on inorganic growth opportunities.</li>
<li>Focus on growing into US, European and Japanese markets.</li>
</ul>
<h2 class="heading" id="qa-insights">
  Q&amp;A Insights
  <a class="anchor" href="#qa-insights">#</a>
</h2>
<h3 class="heading" id="most-pressing-analyst-questions">
  Most Pressing Analyst Questions
  <a class="anchor" href="#most-pressing-analyst-questions">#</a>
</h3>
<ul>
<li>Details on customer interactions and conversion rates.</li>
<li>Breakdown of Pyridine derivatives and their contribution.</li>
<li>Retention of the new leadership team.</li>
<li>Market size and applications for oil field chemicals.</li>
<li>Asset turnover expectations for Specialty Chemicals.</li>
<li>Capex funding strategy.</li>
<li>Incremental savings plan and drivers.</li>
<li>Inorganic growth strategy.</li>
<li>Impact of US tariffs.</li>
<li>CDMO pipeline mix (pyridine vs. non-pyridine).</li>
<li>Pharma CDMO differentiation from Jubilant Pharmova.</li>
</ul>
<h3 class="heading" id="new-information-revealed">
  New Information Revealed
  <a class="anchor" href="#new-information-revealed">#</a>
</h3>
<ul>
<li>70% of Pharma CDMO business is currently non-pyridine.</li>
<li>One of the two major Agro CDMO contracts is non-pyridine.</li>
<li>Actively looking at inorganic growth opportunities.</li>
<li>Detailed breakdown of cost-saving initiatives.</li>
<li>The future revenue growth mix of Pyridine and Non-Pyridine based chemicals.</li>
</ul>
<h2 class="heading" id="management-tone--sentiment">
  Management Tone &amp; Sentiment
  <a class="anchor" href="#management-tone--sentiment">#</a>
</h2>
<h3 class="heading" id="overall-tone">
  Overall Tone
  <a class="anchor" href="#overall-tone">#</a>
</h3>
<ul>
<li>Confident, optimistic, and focused.</li>
</ul>
<h3 class="heading" id="changes-in-language">
  Changes in Language
  <a class="anchor" href="#changes-in-language">#</a>
</h3>
<ul>
<li>More emphasis on customer centricity, innovation, and ESG.</li>
</ul>
<h3 class="heading" id="areas-of-confidenceconcern">
  Areas of Confidence/Concern
  <a class="anchor" href="#areas-of-confidenceconcern">#</a>
</h3>
<ul>
<li>Confidence: CDMO, Fine Chemicals, Nutrition, strategic shift, operational improvements, ESG initiatives.</li>
<li>Concern: Market volatility and competition in Chemical Intermediates (acetyls), but with a plan to address it.</li>
</ul>
<h2 class="heading" id="summary-of-most-important-takeaways">
  Summary of Most Important Takeaways
  <a class="anchor" href="#summary-of-most-important-takeaways">#</a>
</h2>
<ul>
<li>Jubilant Ingrevia is undergoing a significant transformation, shifting its focus from Chemical Intermediates to higher-margin Specialty Chemicals and Nutrition businesses.</li>
<li>The &ldquo;Pinnacle 345&rdquo; strategy outlines ambitious growth targets (3x revenue, 4x EBITDA by FY30), driven by CDMO, Fine Chemicals, and expansion in new areas like cosmetics and semiconductors.</li>
<li>The company has made substantial progress in the last 1.5 years, with organizational restructuring, increased R&amp;D investment, and digital interventions.</li>
<li>While market challenges exist (particularly in acetyls), management is confident in their ability to execute their strategy and deliver on their targets.</li>
<li>The emphasis on customer centricity, innovation, and ESG positions the company for sustainable long-term growth. The company is also clearly focused on increasing exports, exploring inorganic growth opportunities, and are well-funded to meet their objectives.</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7181505-1b57-41e6-b472-9f0eb044c61c.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/care-ratings-ltdannual-report-2023-24-analysis/">
                        CARE Ratings Ltd:Annual Report 2023-24 Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/irfctherailwaystockthatjust-got-a-major-upgrade-what-it-means-for-investors/">
                        IRFC The Railway Stock That Just Got a Major Upgrade - What It Means for Investors
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>